Empty IV Bags Market by Material Type (Non-PVC, PVC), Volume (100 mL, 1000 mL, 250 mL), End User, Distribution Channel, Application - Global Forecast 2025-2032
Description
The Empty IV Bags Market was valued at USD 4.00 billion in 2024 and is projected to grow to USD 4.23 billion in 2025, with a CAGR of 5.69%, reaching USD 6.24 billion by 2032.
A focused orientation that prepares procurement, clinical operations, and commercial leaders to navigate material, regulatory, and distribution complexities in IV bag sourcing
This executive summary distills essential insights into the evolving landscape for empty intravenous (IV) bags, offering a concise orientation for senior leaders, supply chain managers, and clinical procurement teams. The content synthesizes recent changes in regulatory posture, materials innovation, distribution models, and end-user demand drivers that collectively shape procurement priorities and product strategies across infusion therapy. The purpose is to equip decision-makers with an integrated perspective that clarifies where resilience investments and commercial focus deliver the most immediate operational benefits.
Through a structured assessment of material choices, volume preferences, application mixes, and distribution dynamics, the reader will gain a clear sense of the levers that influence product selection, supplier negotiations, and inventory planning. The narrative emphasizes pragmatic considerations such as compatibility with critical drug formulations, storage and transport attributes, and the operational impacts of transitioning between materials or packaging formats. By highlighting cross-cutting themes and emergent risks, the introduction prepares stakeholders for deeper sections that address regulatory shifts, tariff impacts, segmentation nuances, regional differences, and recommended actions to sustain supply and competitiveness.
A concise synthesis of material innovation, distribution evolution, and regulatory pressure reshaping how suppliers and buyers prioritize IV bag design and sourcing
The infusion ecosystem is undergoing transformative shifts driven by material substitution, supply chain reconfiguration, and evolving clinical practices that prioritize safety, sustainability, and compatibility. Advances in polymer science and a growing preference for alternatives to traditional PVC have accelerated product redesign efforts, prompting manufacturers and buyers to reassess product specifications, validation protocols, and lifecycle footprints. Concurrently, heightened scrutiny from regulators on leachable profiles and phthalate-related exposures has shifted design priorities toward materials such as EVA and polyethylene, compelling manufacturers to refine extrusion and sterilization processes.
At the same time, distribution and procurement models are becoming more diverse as digital channels and hospital purchasing consortia expand their influence. Online pharmacies and third-party logistics providers are contributing to faster fulfillment cycles while creating new points of quality oversight. Homecare demand has also risen, prompting suppliers to develop user-friendly bag configurations and clearer labeling for non-professional settings. Supplier consolidation and strategic partnerships are realigning manufacturing footprints to prioritize agility and risk mitigation, which in turn affects lead times and qualification cycles for new materials and suppliers. These shifts are reshaping how clinical teams, supply chain departments, and commercial leaders evaluate product portfolios and plan for near- to mid-term operational readiness.
An integrated assessment of how the 2025 US tariff realignments altered sourcing calculus, supplier footprints, and resilience planning across IV bag supply chains
United States tariff adjustments enacted in 2025 have introduced a new layer of cost and regulatory complexity for global supply chains that provide components, raw polymers, and finished infusion bags. The tariff landscape has had a differential impact across materials and manufacturing geographies, altering landed costs and prompting procurement organizations to reassess supplier footprints. For manufacturers that rely on imported resins or specialized components, tariff-driven cost differentials have encouraged nearshoring conversations and deeper scrutiny of total landed cost rather than unit price alone.
In response, several manufacturers and health systems have accelerated qualification protocols for alternative suppliers and increased inventory buffers for critical SKUs to preserve continuity of supply. Procurement teams have enhanced scenario planning, modeling tariff sensitivities alongside transportation and labor variables to identify the most resilient sourcing configurations. Regulatory compliance activities have also been affected because qualification timelines for new materials and suppliers now interact with tariff-impacted timelines for capital investment and capacity reallocation. The net effect is greater emphasis on strategic supplier partnerships, contractual hedges, and regional manufacturing options that collectively reduce exposure to tariff fluctuations while maintaining clinical quality and supply reliability.
A granular segmentation analysis revealing how material, volume, end-user, channel, and application choices drive distinct technical validations and commercial strategies for IV bags
Key segmentation insights clarify how product selection and commercial strategy must align with material, volume, end-user, distribution, and application requirements. Based on Material Type, the market is studied across Non-PVC and PVC, and the Non-PVC is further studied across EVA and Polyethylene, creating discrete technical and validation pathways for each polymer family. Material decisions affect compatibility with drug formulations, sterilization methods, shelf stability, and recycling or disposal protocols, and they therefore cascade across procurement, regulatory approval, and clinical adoption timelines.
Based on Volume, the market is studied across 100 mL, 1000 mL, 250 mL, and 500 mL, which reflects the diversity of dosing regimens and clinical workflows from bolus administration to continuous infusions. Volume selection influences packaging ergonomics, storage footprint, and transport efficiency, and it also ties back to end-user handling preferences. Based on End User, the market is studied across Clinics, Homecare, and Hospitals, with Hospitals further studied across Government Hospitals and Private Hospitals, which highlights the differing purchasing behaviors, regulatory constraints, and inventory philosophies across institutional settings. Public hospitals may prioritize cost containment and standardized SKUs while private hospitals often seek product differentiation and premium features.
Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacy, and Retail Pharmacies, indicating that fulfillment expectations and quality oversight vary markedly across channels. Each channel poses unique requirements for labeling, lot traceability, and cold-chain or ambient handling. Based on Application, the market is studied across Dehydration Therapy, Drug Delivery, and Nutritional Support, and the Nutritional Support category is further studied across Central Nutrition and Peripheral Nutrition, underscoring the technical differences in formulation tolerances, infusion rates, and bag material compatibility. These segmentation lenses together inform how product roadmaps, clinical validation protocols, and commercial positioning must be customized to meet the nuanced needs of each user group and clinical application.
A comparative regional assessment highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape procurement, regulatory, and manufacturing priorities for IV solutions
Regional dynamics exert a significant influence on supply strategies, regulatory pathways, and product preferences across the global infusion landscape. In the Americas, procurement dynamics reflect a mix of centralized group purchasing organizations, large integrated health systems, and a mature private market that values product innovations which reduce clinical risk and improve workflow efficiency. Supply chains in the Americas often prioritize proximity manufacturing and robust distribution networks to minimize lead times and support extensive hospital formularies.
Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous national requirements and varying levels of hospital infrastructure, which create a patchwork of market access considerations. This region frequently balances advanced clinical needs in some markets with capacity-building priorities in others, encouraging suppliers to offer modular solutions that can be validated against diverse regulatory and clinical standards. In Asia-Pacific, rapid expansion of hospital capacity, growing homecare adoption, and local manufacturing investments are reshaping demand patterns. Manufacturers active in the Asia-Pacific region often focus on scaling localized production, optimizing cost-efficiencies for high-volume segments, and tailoring product specifications to meet both urban tertiary hospitals and decentralized care settings. These regional contrasts inform how manufacturers prioritize investments, route-to-market strategies, and regulatory resource allocation to address localized clinical and procurement priorities.
A corporate competitive snapshot showing why technical polymer expertise, validated supply resilience, and integrated partnerships determine leadership in the IV bag ecosystem
Company-level dynamics point to a competitive environment where manufacturing scale, material science capabilities, and regulatory expertise determine strategic advantage. Leading manufacturers are investing in process optimization, polymer compatibility testing, and flexible production lines that can accommodate both PVC-based and non-PVC formulations. Contract manufacturers and specialty converters are increasingly valuable partners because they provide capacity buffers, technical know-how for alternative extrusion techniques, and faster qualification cycles for new formulations.
Strategic partnerships between material suppliers, sterilization service providers, and logistics specialists are becoming more common as companies seek vertically integrated solutions to reduce risk. Investment in quality systems, traceability, and serialization has become a baseline expectation among reputable suppliers, and companies that can demonstrate robust supplier audits and regulatory dossiers gain preferential access to institutional purchasers. At the same time, nimble entrants focusing on sustainable materials or niche volume segments are challenging incumbents by offering lower waste footprints or enhanced compatibility profiles. Overall, companies that combine technical depth in polymer science, validated supply chain resilience, and customer-centric commercial models are best positioned to win long-term contracts and influence clinical specification decisions.
Actionable strategic steps for manufacturers and buying organizations to align material choices, supplier diversity, and clinical validation for resilient IV bag supply chains
Industry leaders should prioritize a coordinated strategy that aligns material innovation, supplier diversification, and regulatory readiness to sustain supply continuity and capture clinical preference. Investing in dual-source qualification for critical polymers and components reduces single-point vulnerabilities while enabling faster response to tariff and trade disruptions. Parallel to supplier diversification, companies should accelerate validation protocols for non-PVC solutions such as EVA and polyethylene, ensuring compatibility with a broad range of drug formulations and sterilization processes to minimize clinical adoption friction.
Commercial teams should work closely with clinical stakeholders to develop evidence dossiers that demonstrate equivalence or superiority in leachable profiles, handling ergonomics, and patient safety. Strengthening distribution resilience through strategic partnerships with hospital pharmacies, online fulfillment platforms, and retail channels will provide multi-channel redundancy and improved access for homecare patients. Finally, embedding sustainability metrics into product development and procurement decisions will address growing institutional priorities and regulatory expectations while unlocking operational efficiencies over the product lifecycle. Together, these actions enable organizations to balance cost, quality, and innovation in a way that supports long-term competitiveness and operational reliability.
A rigorous mixed-methods research approach combining stakeholder interviews, technical dossier analysis, and supply chain mapping to produce practical procurement and design guidance
The research methodology combines a multi-disciplinary approach that synthesizes primary stakeholder interviews, technical dossier reviews, and supply chain mapping to ensure comprehensive coverage. Primary inputs included structured interviews with procurement leads, clinical pharmacists, manufacturing engineers, and distribution partners to surface operational constraints, procurement criteria, and channel-specific expectations. Technical analysis incorporated polymer compatibility testing protocols, sterilization method reviews, and regulatory submission patterns to evaluate the practical implications of material substitutions and design changes.
Secondary analysis drew on publicly available regulatory guidance, trade data, and industry publications to triangulate findings and to contextualize tariff impacts and regional manufacturing trends. Supply chain mapping identified critical nodes, single-source dependencies, and logistics chokepoints, which informed resilience recommendations. Finally, synthesis workshops with domain experts validated the findings and prioritized actionable recommendations based on feasibility, clinical impact, and commercial return. The resulting methodology balances qualitative insights with technical validation to produce a pragmatic roadmap for decision-makers focused on procurement integrity and product innovation.
A succinct conclusion emphasizing why validated material transitions, supplier diversification, and regional manufacturing strategies are essential for durable supply continuity
In conclusion, the empty IV bag sector is at an inflection point where material innovation, regulatory attention, and supply chain dynamics converge to redefine procurement and product strategy. The move toward non-PVC alternatives such as EVA and polyethylene, combined with evolving channel preferences and tariff-influenced sourcing decisions, requires a cohesive response from manufacturers and buyers alike. Emphasizing validated material transitions, diversified supplier networks, and regionally aware manufacturing footprints will be essential to maintaining clinical continuity and seizing opportunities presented by new care delivery models.
Decision-makers should treat the insights in this executive summary as a foundation for targeted initiatives: accelerate technical validations for alternative polymers, strengthen supplier and distribution redundancy, and align commercial narratives with clinical evidence that emphasizes safety, compatibility, and workflow advantages. By taking these steps, stakeholders can reduce operational risk, meet evolving regulatory expectations, and deliver the product attributes clinicians and patients expect in contemporary infusion therapy environments.
Please Note: PDF & Excel + Online Access - 1 Year
A focused orientation that prepares procurement, clinical operations, and commercial leaders to navigate material, regulatory, and distribution complexities in IV bag sourcing
This executive summary distills essential insights into the evolving landscape for empty intravenous (IV) bags, offering a concise orientation for senior leaders, supply chain managers, and clinical procurement teams. The content synthesizes recent changes in regulatory posture, materials innovation, distribution models, and end-user demand drivers that collectively shape procurement priorities and product strategies across infusion therapy. The purpose is to equip decision-makers with an integrated perspective that clarifies where resilience investments and commercial focus deliver the most immediate operational benefits.
Through a structured assessment of material choices, volume preferences, application mixes, and distribution dynamics, the reader will gain a clear sense of the levers that influence product selection, supplier negotiations, and inventory planning. The narrative emphasizes pragmatic considerations such as compatibility with critical drug formulations, storage and transport attributes, and the operational impacts of transitioning between materials or packaging formats. By highlighting cross-cutting themes and emergent risks, the introduction prepares stakeholders for deeper sections that address regulatory shifts, tariff impacts, segmentation nuances, regional differences, and recommended actions to sustain supply and competitiveness.
A concise synthesis of material innovation, distribution evolution, and regulatory pressure reshaping how suppliers and buyers prioritize IV bag design and sourcing
The infusion ecosystem is undergoing transformative shifts driven by material substitution, supply chain reconfiguration, and evolving clinical practices that prioritize safety, sustainability, and compatibility. Advances in polymer science and a growing preference for alternatives to traditional PVC have accelerated product redesign efforts, prompting manufacturers and buyers to reassess product specifications, validation protocols, and lifecycle footprints. Concurrently, heightened scrutiny from regulators on leachable profiles and phthalate-related exposures has shifted design priorities toward materials such as EVA and polyethylene, compelling manufacturers to refine extrusion and sterilization processes.
At the same time, distribution and procurement models are becoming more diverse as digital channels and hospital purchasing consortia expand their influence. Online pharmacies and third-party logistics providers are contributing to faster fulfillment cycles while creating new points of quality oversight. Homecare demand has also risen, prompting suppliers to develop user-friendly bag configurations and clearer labeling for non-professional settings. Supplier consolidation and strategic partnerships are realigning manufacturing footprints to prioritize agility and risk mitigation, which in turn affects lead times and qualification cycles for new materials and suppliers. These shifts are reshaping how clinical teams, supply chain departments, and commercial leaders evaluate product portfolios and plan for near- to mid-term operational readiness.
An integrated assessment of how the 2025 US tariff realignments altered sourcing calculus, supplier footprints, and resilience planning across IV bag supply chains
United States tariff adjustments enacted in 2025 have introduced a new layer of cost and regulatory complexity for global supply chains that provide components, raw polymers, and finished infusion bags. The tariff landscape has had a differential impact across materials and manufacturing geographies, altering landed costs and prompting procurement organizations to reassess supplier footprints. For manufacturers that rely on imported resins or specialized components, tariff-driven cost differentials have encouraged nearshoring conversations and deeper scrutiny of total landed cost rather than unit price alone.
In response, several manufacturers and health systems have accelerated qualification protocols for alternative suppliers and increased inventory buffers for critical SKUs to preserve continuity of supply. Procurement teams have enhanced scenario planning, modeling tariff sensitivities alongside transportation and labor variables to identify the most resilient sourcing configurations. Regulatory compliance activities have also been affected because qualification timelines for new materials and suppliers now interact with tariff-impacted timelines for capital investment and capacity reallocation. The net effect is greater emphasis on strategic supplier partnerships, contractual hedges, and regional manufacturing options that collectively reduce exposure to tariff fluctuations while maintaining clinical quality and supply reliability.
A granular segmentation analysis revealing how material, volume, end-user, channel, and application choices drive distinct technical validations and commercial strategies for IV bags
Key segmentation insights clarify how product selection and commercial strategy must align with material, volume, end-user, distribution, and application requirements. Based on Material Type, the market is studied across Non-PVC and PVC, and the Non-PVC is further studied across EVA and Polyethylene, creating discrete technical and validation pathways for each polymer family. Material decisions affect compatibility with drug formulations, sterilization methods, shelf stability, and recycling or disposal protocols, and they therefore cascade across procurement, regulatory approval, and clinical adoption timelines.
Based on Volume, the market is studied across 100 mL, 1000 mL, 250 mL, and 500 mL, which reflects the diversity of dosing regimens and clinical workflows from bolus administration to continuous infusions. Volume selection influences packaging ergonomics, storage footprint, and transport efficiency, and it also ties back to end-user handling preferences. Based on End User, the market is studied across Clinics, Homecare, and Hospitals, with Hospitals further studied across Government Hospitals and Private Hospitals, which highlights the differing purchasing behaviors, regulatory constraints, and inventory philosophies across institutional settings. Public hospitals may prioritize cost containment and standardized SKUs while private hospitals often seek product differentiation and premium features.
Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacy, and Retail Pharmacies, indicating that fulfillment expectations and quality oversight vary markedly across channels. Each channel poses unique requirements for labeling, lot traceability, and cold-chain or ambient handling. Based on Application, the market is studied across Dehydration Therapy, Drug Delivery, and Nutritional Support, and the Nutritional Support category is further studied across Central Nutrition and Peripheral Nutrition, underscoring the technical differences in formulation tolerances, infusion rates, and bag material compatibility. These segmentation lenses together inform how product roadmaps, clinical validation protocols, and commercial positioning must be customized to meet the nuanced needs of each user group and clinical application.
A comparative regional assessment highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape procurement, regulatory, and manufacturing priorities for IV solutions
Regional dynamics exert a significant influence on supply strategies, regulatory pathways, and product preferences across the global infusion landscape. In the Americas, procurement dynamics reflect a mix of centralized group purchasing organizations, large integrated health systems, and a mature private market that values product innovations which reduce clinical risk and improve workflow efficiency. Supply chains in the Americas often prioritize proximity manufacturing and robust distribution networks to minimize lead times and support extensive hospital formularies.
Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous national requirements and varying levels of hospital infrastructure, which create a patchwork of market access considerations. This region frequently balances advanced clinical needs in some markets with capacity-building priorities in others, encouraging suppliers to offer modular solutions that can be validated against diverse regulatory and clinical standards. In Asia-Pacific, rapid expansion of hospital capacity, growing homecare adoption, and local manufacturing investments are reshaping demand patterns. Manufacturers active in the Asia-Pacific region often focus on scaling localized production, optimizing cost-efficiencies for high-volume segments, and tailoring product specifications to meet both urban tertiary hospitals and decentralized care settings. These regional contrasts inform how manufacturers prioritize investments, route-to-market strategies, and regulatory resource allocation to address localized clinical and procurement priorities.
A corporate competitive snapshot showing why technical polymer expertise, validated supply resilience, and integrated partnerships determine leadership in the IV bag ecosystem
Company-level dynamics point to a competitive environment where manufacturing scale, material science capabilities, and regulatory expertise determine strategic advantage. Leading manufacturers are investing in process optimization, polymer compatibility testing, and flexible production lines that can accommodate both PVC-based and non-PVC formulations. Contract manufacturers and specialty converters are increasingly valuable partners because they provide capacity buffers, technical know-how for alternative extrusion techniques, and faster qualification cycles for new formulations.
Strategic partnerships between material suppliers, sterilization service providers, and logistics specialists are becoming more common as companies seek vertically integrated solutions to reduce risk. Investment in quality systems, traceability, and serialization has become a baseline expectation among reputable suppliers, and companies that can demonstrate robust supplier audits and regulatory dossiers gain preferential access to institutional purchasers. At the same time, nimble entrants focusing on sustainable materials or niche volume segments are challenging incumbents by offering lower waste footprints or enhanced compatibility profiles. Overall, companies that combine technical depth in polymer science, validated supply chain resilience, and customer-centric commercial models are best positioned to win long-term contracts and influence clinical specification decisions.
Actionable strategic steps for manufacturers and buying organizations to align material choices, supplier diversity, and clinical validation for resilient IV bag supply chains
Industry leaders should prioritize a coordinated strategy that aligns material innovation, supplier diversification, and regulatory readiness to sustain supply continuity and capture clinical preference. Investing in dual-source qualification for critical polymers and components reduces single-point vulnerabilities while enabling faster response to tariff and trade disruptions. Parallel to supplier diversification, companies should accelerate validation protocols for non-PVC solutions such as EVA and polyethylene, ensuring compatibility with a broad range of drug formulations and sterilization processes to minimize clinical adoption friction.
Commercial teams should work closely with clinical stakeholders to develop evidence dossiers that demonstrate equivalence or superiority in leachable profiles, handling ergonomics, and patient safety. Strengthening distribution resilience through strategic partnerships with hospital pharmacies, online fulfillment platforms, and retail channels will provide multi-channel redundancy and improved access for homecare patients. Finally, embedding sustainability metrics into product development and procurement decisions will address growing institutional priorities and regulatory expectations while unlocking operational efficiencies over the product lifecycle. Together, these actions enable organizations to balance cost, quality, and innovation in a way that supports long-term competitiveness and operational reliability.
A rigorous mixed-methods research approach combining stakeholder interviews, technical dossier analysis, and supply chain mapping to produce practical procurement and design guidance
The research methodology combines a multi-disciplinary approach that synthesizes primary stakeholder interviews, technical dossier reviews, and supply chain mapping to ensure comprehensive coverage. Primary inputs included structured interviews with procurement leads, clinical pharmacists, manufacturing engineers, and distribution partners to surface operational constraints, procurement criteria, and channel-specific expectations. Technical analysis incorporated polymer compatibility testing protocols, sterilization method reviews, and regulatory submission patterns to evaluate the practical implications of material substitutions and design changes.
Secondary analysis drew on publicly available regulatory guidance, trade data, and industry publications to triangulate findings and to contextualize tariff impacts and regional manufacturing trends. Supply chain mapping identified critical nodes, single-source dependencies, and logistics chokepoints, which informed resilience recommendations. Finally, synthesis workshops with domain experts validated the findings and prioritized actionable recommendations based on feasibility, clinical impact, and commercial return. The resulting methodology balances qualitative insights with technical validation to produce a pragmatic roadmap for decision-makers focused on procurement integrity and product innovation.
A succinct conclusion emphasizing why validated material transitions, supplier diversification, and regional manufacturing strategies are essential for durable supply continuity
In conclusion, the empty IV bag sector is at an inflection point where material innovation, regulatory attention, and supply chain dynamics converge to redefine procurement and product strategy. The move toward non-PVC alternatives such as EVA and polyethylene, combined with evolving channel preferences and tariff-influenced sourcing decisions, requires a cohesive response from manufacturers and buyers alike. Emphasizing validated material transitions, diversified supplier networks, and regionally aware manufacturing footprints will be essential to maintaining clinical continuity and seizing opportunities presented by new care delivery models.
Decision-makers should treat the insights in this executive summary as a foundation for targeted initiatives: accelerate technical validations for alternative polymers, strengthen supplier and distribution redundancy, and align commercial narratives with clinical evidence that emphasizes safety, compatibility, and workflow advantages. By taking these steps, stakeholders can reduce operational risk, meet evolving regulatory expectations, and deliver the product attributes clinicians and patients expect in contemporary infusion therapy environments.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of biodegradable polymer formulations in empty IV bag production to meet sustainability targets
- 5.2. Integration of RFID tracking and blockchain systems for real-time empty IV bag supply chain transparency
- 5.3. Increased outsourcing of empty IV bag manufacture to specialized CMOs amid global capacity constraints
- 5.4. Rising demand for modular multi-chamber empty IV bags catering to complex drug reconstitution protocols
- 5.5. Stringent regulatory compliance for phthalate-free and low-extractables empty IV bag materials
- 5.6. Shift towards on-site 3D printing of customized empty IV bags in hospital pharmacies for niche therapies
- 5.7. Strategic partnerships between plastic resin suppliers and IV bag manufacturers to secure raw material supply
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Empty IV Bags Market, by Material Type
- 8.1. Non-PVC
- 8.1.1. EVA
- 8.1.2. Polyethylene
- 8.2. PVC
- 9. Empty IV Bags Market, by Volume
- 9.1. 100 mL
- 9.2. 1000 mL
- 9.3. 250 mL
- 9.4. 500 mL
- 10. Empty IV Bags Market, by End User
- 10.1. Clinics
- 10.2. Homecare
- 10.3. Hospitals
- 10.3.1. Government Hospitals
- 10.3.2. Private Hospitals
- 11. Empty IV Bags Market, by Distribution Channel
- 11.1. Hospital Pharmacies
- 11.2. Online Pharmacy
- 11.3. Retail Pharmacies
- 12. Empty IV Bags Market, by Application
- 12.1. Dehydration Therapy
- 12.2. Drug Delivery
- 12.3. Nutritional Support
- 12.3.1. Central Nutrition
- 12.3.2. Peripheral Nutrition
- 13. Empty IV Bags Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Empty IV Bags Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Empty IV Bags Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Baxter International, Inc.
- 16.3.2. B. Braun Melsungen AG
- 16.3.3. Fresenius Kabi AG
- 16.3.4. Terumo Corporation
- 16.3.5. ICU Medical, Inc.
- 16.3.6. Nipro Corporation
- 16.3.7. Grifols, S.A.
- 16.3.8. Vygon S.A.
- 16.3.9. Poly Medicure Limited
- 16.3.10. Wipak Group
- 16.3.11. Technoflex
- 16.3.12. Sippex IV Bags
- 16.3.13. JW Life Science Corp
- 16.3.14. POLYCINE GmbH
- 16.3.15. BAUSCH Advanced Technology Group
- 16.3.16. Becton, Dickinson and Company
- 16.3.17. Amcor LLC
- 16.3.18. Medippex Group
- 16.3.19. LyondellBasell Industries Holdings B.V.
- 16.3.20. Medisca Inc.
- 16.3.21. Tacy Medical Inc.
- 16.3.22. West Pharmaceutical Services Inc.
- 16.3.23. Eurolife Healthcare Pvt Ltd.
- 16.3.24. McGuff Medical Company, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
